CA-XSOLLA
Xsolla, a global video game commerce company, announces the launch of its Mobile Software Development Kit (SDK). Whether you want to expand your payment options, go direct-to-consumer/out-of-store, or simply improve your game’s revenue potential, Xsolla Mobile SDK is the gateway to efficiently and effectively achieve these goals. This release introduces a pivotal solution for the DMA Age, empowering developers worldwide to seamlessly integrate their games on Android and iOS platforms with a global payment solution and web shop. Such integration significantly broadens the potential for mobile game monetization worldwide and unlocks new distribution channels. Game developers like Gaijin Network LTD (Crossout), Artstorm (Modern Warships), LINGCHAI (HONG KONG) LIMITED (Fantasy Tales: Sword and Magic), and ULTRAHORSE (SquadBlast) already use Xsolla SDK to monetize their games.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240718044203/en/
(Graphic: Xsolla)
The launch of the Xsolla Mobile SDK aligns with recent legislative changes worldwide, including in the European Union, particularly the Digital Markets Act (DMA), and confirmed roll-out in Japan and the UK in 2025. This shift represents a critical development in the digital marketplace, providing developers with new monetization avenues to help drive more profits by going beyond traditional app store limitations.
Xsolla’s Mobile SDK Enables Out-of-Store Transactions
Xsolla's Mobile SDK streamlines the process for developers seeking distribution solutions outside the Google Play and App Store. The SDK enables Pay Station to be the primary option for accepting payments for out-of-store transactions. Android developers can integrate it into a self-distributed APK, distributed with channeling partners supporting alternative billing methods. It is also tailored for Web Distribution and App Marketplaces for iOS notarized Apps. Moreover, it is compatible with various game engines, from Unity to Native, making it a versatile and valuable tool for developers looking to enhance their in-game payment experience. Xsolla Mobile SDK complements a Web Shop to enhance out-of-store distribution strategies.
Xsolla’s Mobile SDK Enhances In-Store Transactions with Compliance under DMA
The SDK's features include seamless integration into games already supported by the Google Play Billing Library or Apple StoreKit integrations. Xsolla's Mobile SDK provides additional functionality or replaces billing options tailored to meet Google Play (UCB) and Apple's requirements under the Digital Markets Act (DMA). With Xsolla’s Mobile SDK, games can accept payments with 700+ local payment methods in 200+ territories.
As new regulations emerge, this SDK ensures a smooth expansion to new billing models while maintaining compliance with platform requirements powered by Xsolla Pay Station in other regions.
"With the introduction of our Mobile SDK, Xsolla reaffirms its commitment to supporting mobile game developers through the evolving digital and regulatory economy," said David Stelzer, President of Xsolla. "We're here to help developers navigate the regulatory and compliance changes easily, providing them with the tools to expand their payment options, reduce commission costs, and ultimately drive greater profitability for their mobile games."
The newly released Xsolla Mobile SDK for Android has been available for developers worldwide since today, with iOS support in early access available for those operating within the European Union.
Developers can access the SDK and detailed integration guides by visiting:
Xsolla's Developer Portal
Xsolla Mobile SDK
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718044203/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom